Literature DB >> 9452970

Integrated functions for four basic models of indirect pharmacodynamic response.

W Krzyzanski1, W J Jusko.   

Abstract

The integrated solutions (ABEC, area between baseline and effect curve) of four basic models of indirect pharmacodynamic responses are developed. These models assume that drug can inhibit or stimulate the production or loss of the response variable. For two models (I and III) with monoexponential drug disposition, explicit formulas for the ABEC were obtained, where ABEC is a function of ln (1 + (D/V)/IC50) or ln (1 + (D/V)/SC50) where D = dose, V = volume, and IC50 or SC50 = 50% effective concentration. Two other models (II and IV) were treated asymptotically with respect to small and large doses. Approximate formulas [e.g., ABEC = constant(1) x ln (1 + (D/V)/IC50) + constant (2)] were derived and the asymptotic behavior of the ABEC was established. In addition, simulations were performed to assess the effects of drug absorption rates and polyexponential disposition on ABEC values. These models show how pharmacokinetic and pharmacodynamic factors jointly determine the net response to a single dose of drug.

Entities:  

Mesh:

Year:  1998        PMID: 9452970     DOI: 10.1021/js970168r

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

1.  Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Characterization of pharmacodynamic recession slopes for direct and indirect response models.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

3.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

4.  A dynamical systems analysis of the indirect response model with special emphasis on time to peak response.

Authors:  Lambertus A Peletier; Johan Gabrielsson; Jacintha den Haag
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Assessment of basic indirect pharmacodynamic response models with physiological limits.

Authors:  Zhenling Yao; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04       Impact factor: 2.745

6.  Characterization of four basic models of indirect pharmacodynamic responses.

Authors:  A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

7.  Landmark and longitudinal exposure-response analyses in drug development.

Authors:  Chuanpu Hu; Honghui Zhou; Amarnath Sharma
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-07-20       Impact factor: 2.745

8.  Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Authors:  Rui Zhu; Yanan Zheng; Wendy S Putnam; Jennifer Visich; Mark D Eisner; John G Matthews; Karin E Rosen; David Z D'Argenio
Journal:  AAPS J       Date:  2013-02-15       Impact factor: 4.009

9.  A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides.

Authors:  D Czock; M Giehl; F Keller
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 10.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.